GLP-1 receptor agonists

GLP-1 receptor agonists are drugs that activate the receptor for glucagon-like peptide-1, a hormone released by the gut after a meal; most are engineered peptides rebuilt to survive in the bloodstream for days rather than minutes. They lower blood glucose, slow gastric emptying, and act on brainstem and hypothalamic circuits to reduce food intake, and in adults with obesity the newer agents produce weight loss that no earlier drug approached. Whether that makes them a longevity intervention is the argument this article is about: they demonstrably treat conditions that shorten life, and nothing shows that they change the rate at which anyone ages.

§How they work

GLP-1 is secreted by enteroendocrine cells lining the distal small intestine and colon when nutrients arrive. It amplifies insulin release in a glucose-dependent way, which is why these drugs rarely cause hypoglycaemia on their own; it suppresses glucagon; it slows gastric emptying; and it binds receptors in the hypothalamus and the area postrema, where the signal registers as satiety.¹ The native peptide is destroyed within a few minutes by the enzyme DPP-4, so the problem for drug developers was how to make the hormone last.

Two solutions have prevailed. The first came from a lizard: exendin-4, isolated from Gila monster venom, is naturally resistant to DPP-4 and activates the human receptor, and became exenatide.² The second is chemical modification of the human sequence, combining amino-acid substitutions with a fatty-acid chain that binds circulating albumin and slows both enzymatic degradation and renal clearance. That combination makes liraglutide a once-daily injection and semaglutide a once-weekly one.

Most of the weight loss follows from eating less. That resemblance to a caloric deficit is what first drew attention from biogerontology, though the analogy to Caloric restriction is loose: dietary restriction experiments hold lean animals below their normal intake, while these drugs mainly remove excess adiposity from people who have it. Whether any of the cardiovascular or renal benefit is independent of weight loss is unsettled and under active research.

Terminology

GLP-1 and GIP are the two incretin hormones. Semaglutide, made by Novo Nordisk and sold as Ozempic for type 2 diabetes and Wegovy for weight management, acts at the GLP-1 receptor only, as do liraglutide, dulaglutide, and exenatide. Tirzepatide, Eli Lilly's Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist and is not a GLP-1 agonist in the strict sense; Retatrutide adds a glucagon receptor arm. Orforglipron, Lilly's Foundayo, is a GLP-1 agonist that is not a peptide at all but a small molecule taken as a daily pill, while eloralintide acts at the amylin receptor. Press coverage collapses all of these into "GLP-1s", which obscures real pharmacological differences.

§Development history

1. 1987
   Incretin action established
   Work in several laboratories shows that the GLP-1 fragment released after eating stimulates insulin secretion, identifying it as a physiological incretin.
2. 1992
   Exendin-4 isolated
   John Eng and colleagues characterize a DPP-4-resistant GLP-1 receptor agonist in the venom of the Gila monster, the peptide that becomes exenatide.
3. 2005
   First approval
   Exenatide is approved in the United States for type 2 diabetes, twice-daily by injection.
4. 2010
   Liraglutide reaches market
   Novo Nordisk's daily analogue is approved for type 2 diabetes; a higher-dose version is approved for weight management in 2014.
5. 2016-2017
   Cardiovascular benefit and semaglutide
   The LEADER trial reports fewer major cardiovascular events with liraglutide in people with type 2 diabetes at high cardiovascular risk (2016). Once-weekly semaglutide is approved for type 2 diabetes in 2017; an oral tablet formulation follows in 2019.
6. 2021
   Obesity result and shortage
   STEP 1 reports roughly 15 percent mean weight loss over 68 weeks and semaglutide is approved for weight management; demand outstrips manufacturing capacity for the next several years.
7. 2022
   Dual agonism
   Tirzepatide, targeting both the GIP and GLP-1 receptors, is approved for type 2 diabetes; SURMOUNT-1 reports mean weight loss around a fifth of body weight at the highest dose.
8. 2023
   Outcomes without diabetes
   SELECT reports fewer major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease but no diabetes; tirzepatide is approved for obesity.
9. 2024
   Beyond weight and glucose
   The FLOW trial, halted early for efficacy the previous year, reports slower kidney-disease progression with semaglutide in type 2 diabetes. Labels expand toward cardiovascular risk reduction and, for tirzepatide, obstructive sleep apnoea.
10. 2025
    Liver, brain and a pill
    Semaglutide receives US accelerated approval for MASH with liver fibrosis, fails to slow early Alzheimer's disease in two phase 3 trials, and in December is approved as the Wegovy pill, the first oral GLP-1 drug for weight management.
11. 2026
    Small molecules and generics
    The FDA approves orforglipron (Foundayo), a non-peptide oral agonist, for weight management, and tirzepatide for cardiovascular risk reduction in type 2 diabetes. Generic semaglutide goes on sale in India and is authorized in Canada.

§What the trials show

The weight results exceed those of any previously approved weight-loss drug. In STEP 1, adults with overweight or obesity and without diabetes lost roughly 15 percent of body weight on average over 68 weeks on semaglutide, against about 2 percent on placebo.³ Tirzepatide, at its highest dose in SURMOUNT-1, averaged around a fifth.⁴ Means conceal a wide spread: a substantial minority lose very little, and both trials gave every participant diet and activity counselling alongside the injection.

The strongest hard-outcome evidence is the SELECT cardiovascular outcomes trial, which enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes, and reported a relative reduction of roughly a fifth in a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke over about three years.⁵ The absolute difference was a small number of percentage points, in a population already at high risk. Deaths from any cause were fewer in the treated group, a difference the trial's statistical hierarchy did not establish as a confirmed result. Regulators subsequently expanded semaglutide's label to cardiovascular risk reduction.

Tirzepatide's outcomes trial set a different test. SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, a GLP-1 agonist already shown to reduce cardiovascular events, rather than to placebo. Tirzepatide was non-inferior (hazard ratio 0.92, 95.3 percent confidence interval 0.83-1.01), but superiority was not established.⁶ On that basis the FDA approved Mounjaro in August 2026 to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them; the indication does not extend to obesity without diabetes.⁷

Other organ systems have followed. Semaglutide slowed progression of kidney disease in people with type 2 diabetes and chronic kidney disease,⁸ and in 2025 it received US accelerated approval for metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, on the strength of liver-biopsy results at 72 weeks.⁹ Trials have reported improved symptoms in heart failure with preserved ejection fraction, reduced severity of obstructive sleep apnoea with tirzepatide, and reduced knee osteoarthritis pain. The failures are as informative: Novo Nordisk reported in late 2025 that two large trials of oral semaglutide in early Alzheimer's disease did not slow progression of the disease, the most direct test so far of the claim that incretin drugs act broadly on age-related disease rather than through metabolism.¹⁰ The full results, published in 2026, showed no significant difference from placebo on the primary dementia-rating endpoint at 104 weeks across 3,808 participants.¹¹

§The geroscience argument

The case for treating this class as a longevity intervention is a population argument rather than a biological one. Obesity and type 2 diabetes are among the largest modifiable contributors to premature death, and they accelerate several of the Hallmarks of aging: chronic low-grade inflammation of the kind described under Inflammaging, accumulation of senescent cells in adipose tissue as covered under Cellular senescence, vascular and renal damage. A drug that reverses those at scale could move population life expectancy further than any candidate geroprotector now in trials has any prospect of doing, which is the The longevity dividend argument arriving from an unexpected direction. Proponents add that one agent delaying several apparently unrelated age-related conditions is the shape of result the Geroscience hypothesis predicts, and the shape the TAME trial was designed to produce.

The case against is that the drugs are doing what any effective disease treatment does. Restoring someone with obesity toward the metabolic state of someone who never had it returns them to a baseline; it does not push past it. Nothing in the record shows a change in the underlying rate of aging, and the animal work, overwhelmingly in rodents, has measured metabolic and body-weight endpoints rather than lifespan. The distinction is exactly the one that separates this class from Rapamycin and the other candidate geroprotectors, whose whole claim is that they act on aging upstream of any particular disease. On the evidence to date, GLP-1 agonists remove an accelerator; they do not slow the clock.

Removing an accelerator or slowing the clock

If the whole benefit runs through weight and glucose, these are excellent drugs for two diseases and say nothing about aging. If part of it is direct receptor signalling in vessels, kidney, and brain, they belong in the geroprotector conversation. The Alzheimer's failure is evidence for the first reading. Nobody has run the trial that would settle it, and movement in an Epigenetic clocks reading or another composite aging measure would not settle it either, because a change in a prediction is not a change in an outcome.

§Limitations

Stopping reverses almost everything. The extension of STEP 1 followed participants after withdrawal and found most of the lost weight returning within about a year, with blood pressure and lipid improvements reverting alongside it.¹² These are therefore chronic medications on the model of antihypertensives, not courses of treatment, and real-world analyses report that a large share of patients stop within the first year because of cost, side effects, or both. An intervention that works only while it is being paid for has a different relationship to healthy lifespan than one that produces a durable change.

A substantial share of the weight lost is lean tissue rather than fat. Body-composition substudies consistently report this, and the proportion is broadly what a caloric deficit of similar size produces by any route, but it is a sharper concern here because the drugs are increasingly used by older adults in whom muscle loss is itself a driver of frailty. Trials pairing incretin drugs with antibodies against the activin and myostatin pathways are underway, and resistance training is the countermeasure with the longest evidence base. Here, as elsewhere, the exercise literature is the comparator any drug has to beat.

§Risks

Gastrointestinal effects dominate the adverse-event profile: nausea, vomiting, diarrhoea, and constipation are common, largely dose-related, and the main reason people discontinue. Gallbladder disease is more frequent with rapid weight loss, and pancreatitis is rare and contested. Delayed gastric emptying has prompted anaesthesiology societies to issue guidance on aspiration risk before elective procedures. Signals raised in observational data are resolved case by case: a rare optic-nerve condition prompted a European safety review that ended in a label change, while other reported associations remain unconfirmed.

The rodent thyroid finding

Long-term dosing produced thyroid C-cell tumours in rats and mice, which is the basis for a boxed warning and a contraindication in people with a personal or family history of medullary thyroid carcinoma. Rodent C-cells express the GLP-1 receptor far more abundantly than human ones do, and no corresponding human effect has been demonstrated. The warning reflects an open question; the finding has not been shown to transfer to humans.

§Access and cost

Supply constrained the market for several years after 2021, and in the United States that shortage legally permitted compounding pharmacies to sell copies, an unregulated parallel supply that contracted once the shortages were declared resolved. In February 2026 the FDA announced it would restrict the ingredients used in mass-marketed compounded versions, the day after a telehealth company began selling a compounded semaglutide pill, which it then withdrew.¹³ Price is the binding constraint now. US list prices sit on the order of a thousand dollars a month before rebates, several times what the same products cost in other high-income countries; manufacturers have opened self-pay channels from about $150 to the mid-hundreds a month;¹⁴ payers have restricted eligibility or withdrawn coverage for weight indications on budget grounds.

Federal deals have started to move those numbers. Agreements the White House announced with Lilly and Novo Nordisk in November 2025 set a $245 monthly Medicare price for Ozempic, Wegovy, Mounjaro and Zepbound, with a $50 monthly copay for beneficiaries, and lower cash prices through the government's TrumpRx site.¹⁵ A Medicare pilot, the GLP-1 Bridge, began covering Wegovy, the Zepbound KwikPen and Foundayo for weight loss on 1 July 2026 at that copay, with prior authorization and body-mass and comorbidity criteria, and is scheduled to run to the end of 2027.¹⁶ Novo Nordisk has said it will cut the US list price of its semaglutide products to $675 a month from January 2027.¹⁷ Uptake is rising faster than prices are falling: Lilly reported third-quarter 2026 revenue up 39 percent, with volume up 53 percent and realized prices down 15 percent across its products, led by Mounjaro and Zepbound.¹⁸

Patents on the earlier agents have begun to lapse in some markets, the usual route to a price collapse, and semaglutide's have now lapsed in some markets outside the United States. In India, where its patent expired in March 2026, generic injections launched from about 1,290 rupees ($14) a month (Natco's vial price), against roughly 10,480 rupees for the starting dose of Novo Nordisk's Wegovy pen,¹⁹ and weeks later Canada became the first G7 country to authorize generic semaglutide, approved for type 2 diabetes.²⁰

Obesity prevalence is rising fastest in middle-income countries, where these drugs are furthest out of reach, making this a clear current example of the pattern described under Access and inequality: an effective intervention distributed inversely to need. Cosmetic use by people at or near typical weight raises the treatment-enhancement boundary that enhancement ethics has argued over for decades, with the added feature that supply diverted to it is supply unavailable to someone with diabetes. The drugs also anchor a consumer metabolic-monitoring market, Continuous glucose monitoring and Wearable health sensors among it, selling the same premise of managed metabolism, while displacing a weight-loss supplement trade built on far weaker evidence.

§Outlook

Oral agents have started to arrive. The FDA approved the Wegovy pill, a daily 25 mg semaglutide tablet, for weight management in December 2025,²¹ and in April 2026 approved orforglipron as Foundayo, a non-peptide small molecule that Lilly markets as a pill taken at any time of day without food or water restrictions.¹⁴ In its 72-week phase 3 trial in adults with obesity, the top dose of orforglipron lowered body weight by 11.2 percent against 2.1 percent on placebo,²² a smaller average than the injectable trials above reported, though the trials are not directly comparable. Lilly reported $184 million of Foundayo sales in the third quarter of 2026, its second quarter on the market.¹⁸

The pipeline is also moving toward multi-agonists combining GLP-1 with GIP, glucagon, or amylin receptor activity, and toward combinations designed to spare muscle. In a 48-week phase 2b trial in adults with overweight or obesity and type 2 diabetes, Lilly reported that the amylin agonist eloralintide added to the top dose of tirzepatide produced 23.3 percent average weight loss on the company's efficacy estimand, against 14.8 percent for tirzepatide alone, with more discontinuations for adverse events in the combination arms than with tirzepatide alone. Those are company-reported conference results, not a peer-reviewed paper, and Lilly plans phase 3 trials from the end of 2026.²³ If oral agents at generic prices arrive, the access argument changes shape and the question becomes what happens when a large fraction of a population takes an appetite-modifying drug indefinitely, a natural experiment with no precedent and no control group.

What remains unanswered is whether any of this shows up where it would count. Population life expectancy responds to metabolic disease with a lag of decades and is confounded by everything else in those decades, so the claim that incretin drugs bought a country years of life will be hard to establish and correspondingly easy to assert. The stronger and more testable claim is narrower: that they compress the years of illness at the end of a life without moving its end, which is Compression of morbidity rather than any change in Maximum human lifespan. That is a large achievement, but not the one the popular framing has settled on.

§See also

• Geroscience hypothesis
• Metformin and the TAME trial
• Caloric restriction
• Exercise as a geroprotector
• Healthspan
• Compression of morbidity
• Access and inequality
• Continuous glucose monitoring

§References